Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe, and Asia. The company is headquartered in George Town, the Cayman Islands. Show more

901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO, CA, UNITED STATES, 94080, South San Francisco, CA, 94080, USA

https://www.theravance.com

BIOTECHNOLOGY

HEALTHCARE

Start AI Chat

Market Cap

885.2M

52 Wk Range

$13.08 - $21.03

Previous Close

$17.04

Open

$17.04

Volume

414,568

Day Range

$17.02 - $17.06

Enterprise Value

535.3M

Cash

219.8M

Avg Qtr Burn

-8.881M

Insider Ownership

4.61%

Institutional Own.

94.68%

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
TRELEGY ELLIPTA Details Asthma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TRELEGY ELLIPTA Details Chronic obstructive pulmonary disease (COPD)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
YUPELRI® (revefenacin) Details Chronic obstructive pulmonary disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ampreloxetine (TD-9855) Details Multiple System Atrophy, Neurogenic orthostatic hypotension	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Nezulcitinib (TD-0903) (Janus kinase inhibitor (JAKi)) Details COVID-19, Skin disease/disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Izencitinib (TD-1473) (GUT-SELECTIVE JAK INHIBITOR) Details Crohns disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Izencitinib (TD-1473) (GUT-SELECTIVE JAK INHIBITOR) Details Inflammatory bowel disease, Inflammatory disease, Ulcerative colitis, Crohns disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.